Search

Your search keyword '"Wei, Michael C."' showing total 288 results
Start Over Author "Wei, Michael C."
288 results on '"Wei, Michael C."'

1. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Author

Sehn, Laurie H., Bartlett, Nancy L., Matasar, Matthew J., Schuster, Stephen J., Assouline, Sarit E., Giri, Pratyush, Kuruvilla, John, Shadman, Mazyar, Cheah, Chan Yoon, Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta J., Wei, Michael C., Yin, Shen, To, Iris, Kaufman, Derrick, Kwan, Antonia, Penuel, Elicia, Bolen, Christopher R., and Budde, Lihua E.

Published
2025
Full Text
View/download PDF

2. Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Author

Chong, Elise A., Penuel, Elicia, Napier, Ellen B., Lundberg, Rachel K., Budde, Lihua E., Shadman, Mazyar, Matasar, Matthew J., Bartlett, Nancy L., Flinn, Ian W., Bosch, Francesc, Fay, Keith, Goy, Andre, Kumar, Anita, Nastoupil, Loretta J., Wei, Michael C., Wu, Mei, Yin, Shen, Fraietta, Joseph A., Chong, Emeline R., and Schuster, Stephen J.

Published
2025
Full Text
View/download PDF

6. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Author

Bartlett, Nancy L., Assouline, Sarit, Giri, Pratyush, Schuster, Stephen J., Cheah, Chan Y., Matasar, Matthew, Gregory, Gareth P., Yoon, Dok Hyun, Shadman, Mazyar, Fay, Keith, Yoon, Sung-Soo, Panizo, Carlos, Flinn, Ian, Johnston, Anna, Bosch, Francesc, Sehn, Laurie H., Wei, Michael C., Yin, Shen, To, Iris, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, and Budde, Lihua E.

Published
2023
Full Text
View/download PDF

7. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Author

Budde, Lihua E, Sehn, Laurie H, Matasar, Matthew, Schuster, Stephen J, Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Canales, Miguel, Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta, Cheah, Chan Yoon, Wei, Michael C, Yin, Shen, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, and Bartlett, Nancy L

Published
2022
Full Text
View/download PDF

8. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

Author

Casulo, Carla, Larson, Melissa C, Lunde, Julianne J, Habermann, Thomas M, Lossos, Izidore S, Wang, Yucai, Nastoupil, Loretta J, Strouse, Christopher, Chihara, Dai, Martin, Peter, Cohen, Jonathon B, Kahl, Brad S, Burack, W Richard, Koff, Jean L, Mun, Yong, Masaquel, Anthony, Wu, Mei, Wei, Michael C, Shewade, Ashwini, Li, Jia, Cerhan, James, Flowers, Christopher R, Link, Brian K, and Maurer, Matthew J

Published
2022
Full Text
View/download PDF

9. Automated Lugano Metabolic Response Assessment in 18F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on 18F-Fluorodeoxyglucose–Positron Emission Tomography

Author

Jemaa, Skander, primary, Ounadjela, Souhila, additional, Wang, Xiaoyong, additional, El-Galaly, Tarec C., additional, Kostakoglu, Lale, additional, Knapp, Andrea, additional, Ku, Grace, additional, Musick, Lisa, additional, Sahin, Denis, additional, Wei, Michael C., additional, Yin, Shen, additional, Bengtsson, Thomas, additional, De Crespigny, Alex, additional, and Carano, Richard A.D., additional

Published
2024
Full Text
View/download PDF

10. Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).

Author

Assouline, Sarit, primary, Budde, Lihua Elizabeth, additional, Chavez, Julio C., additional, Diefenbach, Catherine S., additional, Dorritie, Kathleen Anne, additional, Ghosh, Nilanjan, additional, Olszewski, Adam J, additional, Lossos, Izidore S., additional, Mehta, Amitkumar, additional, Modi, Dipenkumar, additional, Naik, Seema, additional, Smith, Stephen Douglas, additional, Makadia, Sneha, additional, Pham, Song, additional, Wu, Hao, additional, Batlevi, Connie Lee, additional, To, Iris, additional, Wei, Michael C., additional, and Kamdar, Manali, additional

Published
2024
Full Text
View/download PDF

12. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Author

Budde, Lihua E., primary, Assouline, Sarit, additional, Sehn, Laurie H., additional, Schuster, Stephen J., additional, Yoon, Sung-Soo, additional, Yoon, Dok Hyun, additional, Matasar, Matthew J., additional, Bosch, Francesc, additional, Kim, Won Seog, additional, Nastoupil, Loretta J., additional, Flinn, Ian W., additional, Shadman, Mazyar, additional, Diefenbach, Catherine, additional, Cheah, Chan Yoon, additional, Ma, Connie Y., additional, Huang, Huang, additional, Kwan, Antonia, additional, Wei, Michael C., additional, Yin, Shen, additional, and Bartlett, Nancy L., additional

Published
2024
Full Text
View/download PDF

14. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

Author

Budde, Lihua E., primary, Olszewski, Adam J., additional, Assouline, Sarit, additional, Lossos, Izidore S., additional, Diefenbach, Catherine, additional, Kamdar, Manali, additional, Ghosh, Nilanjan, additional, Modi, Dipenkumar, additional, Sabry, Waleed, additional, Naik, Seema, additional, Mehta, Amitkumar, additional, Nakhoda, Shazia K., additional, Smith, Stephen D., additional, Dorritie, Kathleen, additional, Jia, Ting, additional, Pham, Song, additional, Huw, Ling-Yuh, additional, Jing, Jing, additional, Wu, Hao, additional, Ead, Wahib S., additional, To, Iris, additional, Batlevi, Connie Lee, additional, Wei, Michael C., additional, and Chavez, Julio C., additional

Published
2023
Full Text
View/download PDF

15. IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

Author

Budde, Elizabeth L, Sehn, Laurie H, Matasar, Matthew, Schuster, Stephen J, Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Canales, Miguel, Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta, Wei, Michael C, Yin, Shen, Doral, Michelle Y, Li, Chi-Chung, Huang, Huang, Negricea, Raluca, Penuel, Elicia, O'Hear, Carol, and Bartlett, Nancy L

Published
2022
Full Text
View/download PDF

17. Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens

Author

Matheny, Christina J, Wei, Michael C, Bassik, Michael C, Donnelly, Alicia J, Kampmann, Martin, Iwasaki, Masayuki, Piloto, Obdulio, Solow-Cordero, David E, Bouley, Donna M, Rau, Rachel, Brown, Patrick, McManus, Michael T, Weissman, Jonathan S, and Cleary, Michael L

Subjects
Biological Sciences, Medicinal and Biomolecular Chemistry, Chemical Sciences, Stem Cell Research, Biotechnology, Rare Diseases, Hematology, Genetics, Cancer, Pediatric, Pediatric Cancer, Childhood Leukemia, 5.1 Pharmaceuticals, Animals, Antineoplastic Agents, Apoptosis, Benzamides, Cell Cycle, Cell Survival, Cytokines, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Enzyme Inhibitors, High-Throughput Screening Assays, Humans, Male, Mice, Mice, Inbred NOD, Mice, SCID, Molecular Structure, Nicotinamide Phosphoribosyltransferase, Phenotype, Picolines, Structure-Activity Relationship, Tumor Cells, Cultured
Abstract

Phenotypic high-throughput chemical screens allow for discovery of small molecules that modulate complex phenotypes and provide lead compounds for novel therapies; however, identification of the mechanistically relevant targets remains a major experimental challenge. We report the application of sequential unbiased high-throughput chemical and ultracomplex small hairpin RNA (shRNA) screens to identify a distinctive class of inhibitors that target nicotinamide phosphoribosyl transferase (NAMPT), a rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide, a crucial cofactor in many biochemical processes. The lead compound STF-118804 is a highly specific NAMPT inhibitor, improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia, and targets leukemia stem cells. Tandem high-throughput screening using chemical and ultracomplex shRNA libraries, therefore, provides a rapid chemical genetics approach for seamless progression from small-molecule lead identification to target discovery and validation.

Published
2013

18. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

Author

Abramson, Vandana G., Oliveira, Mafalda, Cervantes, Andrés, Wildiers, Hans, Patel, Manish R., Bauer, Todd M., Bedard, Philippe L., Becerra, Carlos, Richey, Stephen, Wei, Michael C., Reyner, Eric, Bond, John, Cui, Na, Wilson, Timothy R., Moore, Heather M., Saura, Cristina, and Krop, Ian E.

Published
2019
Full Text
View/download PDF

19. Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy

Author

McGough, Sarah F., primary, Shamas, Natasha, additional, Wang, Jue, additional, Jaber, Mahmoud, additional, Swarup, Binay, additional, Blanchet Zumofen, Marie-Hélène, additional, Lautié, Bertrand, additional, Parreira, Joana, additional, Wei, Michael C., additional, and Shewade, Ashwini, additional

Published
2023
Full Text
View/download PDF

20. IBCL-489 Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Author

Cheah, Chan Yoon, primary, Bartlett, Nancy L., additional, Assouline, Sarit, additional, Schuster, Stephen J., additional, Kim, Won Seog, additional, Shadman, Mazyar, additional, Isufi, Iris, additional, Yin, Shen, additional, Doral, Michelle Y., additional, Sit, Jason, additional, Chen, Vivian, additional, Huang, Huang, additional, Zhou, Mingzhu, additional, Wei, Michael C., additional, and Budde, L. Elizabeth, additional

Published
2023
Full Text
View/download PDF

22. POSTER: IBCL-489 Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Author

Cheah, Chan Yoon, primary, Bartlett, Nancy L., additional, Assouline, Sarit, additional, Schuster, Stephen J., additional, Kim, Won Seog, additional, Shadman, Mazyar, additional, Isufi, Iris, additional, Yin, Shen, additional, Doral, Michelle Y., additional, Sit, Jason, additional, Chen, Vivian, additional, Huang, Huang, additional, Zhou, Mingzhu, additional, Wei, Michael C., additional, and Budde, L. Elizabeth, additional

Published
2023
Full Text
View/download PDF

23. POSTER: IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

Author

Bartlett, Nancy L., primary, Sehn, Laurie H., additional, Matasar, Matthew, additional, Schuster, Stephen J., additional, Assouline, Sarit, additional, Giri, Pratyush, additional, Kuruvilla, John, additional, Canales, Miguel, additional, Dietrich, Sascha, additional, Fay, Keith, additional, Ku, Matthew, additional, Nastoupil, Loretta, additional, Wei, Michael C., additional, Yin, Shen, additional, To, Iris, additional, Huang, Huang, additional, Min, Juliana, additional, Bolen, Christopher R., additional, Penuel, Elicia, additional, and Budde, L. Elizabeth, additional

Published
2023
Full Text
View/download PDF

24. IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

Author

Bartlett, Nancy L., primary, Sehn, Laurie H., additional, Matasar, Matthew, additional, Schuster, Stephen J., additional, Assouline, Sarit, additional, Giri, Pratyush, additional, Kuruvilla, John, additional, Canales, Miguel, additional, Dietrich, Sascha, additional, Fay, Keith, additional, Ku, Matthew, additional, Nastoupil, Loretta, additional, Wei, Michael C., additional, Yin, Shen, additional, To, Iris, additional, Huang, Huang, additional, Min, Juliana, additional, Bolen, Christopher R., additional, Penuel, Elicia, additional, and Budde, L. Elizabeth, additional

Published
2023
Full Text
View/download PDF

30. Supplementary Table S5. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Author

Dickler, Maura N., primary, Saura, Cristina, primary, Richards, Donald A., primary, Krop, Ian E., primary, Cervantes, Andrés, primary, Bedard, Philippe L., primary, Patel, Manish R., primary, Pusztai, Lajos, primary, Oliveira, Mafalda, primary, Cardenas, Alison K., primary, Cui, Na, primary, Wilson, Timothy R., primary, Stout, Thomas J., primary, Wei, Michael C., primary, Hsu, Jerry Y., primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figures from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Author

Jhaveri, Komal, primary, Chang, Matthew T., primary, Juric, Dejan, primary, Saura, Cristina, primary, Gambardella, Valentina, primary, Melnyk, Anton, primary, Patel, Manish R., primary, Ribrag, Vincent, primary, Ma, Cynthia X., primary, Aljumaily, Raid, primary, Bedard, Philippe L., primary, Sachdev, Jasgit C., primary, Dunn, Lara, primary, Won, Helen, primary, Bond, John, primary, Jones, Surai, primary, Savage, Heidi M., primary, Scaltriti, Maurizio, primary, Wilson, Timothy R., primary, Wei, Michael C., primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

32. Data from CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia

Author

Duque-Afonso, Jesús, primary, Lin, Chiou-Hong, primary, Han, Kyuho, primary, Morgens, David W., primary, Jeng, Edwin E., primary, Weng, Ziming, primary, Jeong, Johan, primary, Wong, Stephen Hon Kit, primary, Zhu, Li, primary, Wei, Michael C., primary, Chae, Hee-Don, primary, Schrappe, Martin, primary, Cario, Gunnar, primary, Duyster, Justus, primary, Xiao, Xiangshu, primary, Sakamoto, Kathleen M., primary, Bassik, Michael C., primary, and Cleary, Michael L., primary

Published
2023
Full Text
View/download PDF

33. Supplemental Methods from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Author

Dickler, Maura N., primary, Saura, Cristina, primary, Richards, Donald A., primary, Krop, Ian E., primary, Cervantes, Andrés, primary, Bedard, Philippe L., primary, Patel, Manish R., primary, Pusztai, Lajos, primary, Oliveira, Mafalda, primary, Cardenas, Alison K., primary, Cui, Na, primary, Wilson, Timothy R., primary, Stout, Thomas J., primary, Wei, Michael C., primary, Hsu, Jerry Y., primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

34. Data from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Author

Dickler, Maura N., primary, Saura, Cristina, primary, Richards, Donald A., primary, Krop, Ian E., primary, Cervantes, Andrés, primary, Bedard, Philippe L., primary, Patel, Manish R., primary, Pusztai, Lajos, primary, Oliveira, Mafalda, primary, Cardenas, Alison K., primary, Cui, Na, primary, Wilson, Timothy R., primary, Stout, Thomas J., primary, Wei, Michael C., primary, Hsu, Jerry Y., primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure S2. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Author

Dickler, Maura N., primary, Saura, Cristina, primary, Richards, Donald A., primary, Krop, Ian E., primary, Cervantes, Andrés, primary, Bedard, Philippe L., primary, Patel, Manish R., primary, Pusztai, Lajos, primary, Oliveira, Mafalda, primary, Cardenas, Alison K., primary, Cui, Na, primary, Wilson, Timothy R., primary, Stout, Thomas J., primary, Wei, Michael C., primary, Hsu, Jerry Y., primary, and Baselga, José, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Data from CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia

Author

Duque-Afonso, Jesús, primary, Lin, Chiou-Hong, primary, Han, Kyuho, primary, Morgens, David W., primary, Jeng, Edwin E., primary, Weng, Ziming, primary, Jeong, Johan, primary, Wong, Stephen Hon Kit, primary, Zhu, Li, primary, Wei, Michael C., primary, Chae, Hee-Don, primary, Schrappe, Martin, primary, Cario, Gunnar, primary, Duyster, Justus, primary, Xiao, Xiangshu, primary, Sakamoto, Kathleen M., primary, Bassik, Michael C., primary, and Cleary, Michael L., primary

Published
2023
Full Text
View/download PDF

37. Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL

Author

Susilo, Monica E., primary, Li, Chi‐Chung, additional, Gadkar, Kapil, additional, Hernandez, Genevive, additional, Huw, Ling‐Yuh, additional, Jin, Jin Y., additional, Yin, Shen, additional, Wei, Michael C., additional, Ramanujan, Saroja, additional, and Hosseini, Iraj, additional

Published
2023
Full Text
View/download PDF

39. SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Author

Westin, Jason, primary, Olszewski, Adam J., additional, Fogliatto, Laura Maria, additional, Kim, Won-Seog, additional, Shin, Ho-Jin, additional, Wu, Hao, additional, Yin, Shen, additional, Pham, Song, additional, Penuel, Elicia, additional, Jing, Jing, additional, Wei, Michael C., additional, and Budde, Elizabeth L., additional

Published
2022
Full Text
View/download PDF

41. Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Author

Bishton, Mark, primary, Woestmann, Corinna, additional, Morschhauser, Franck, additional, Eyre, Toby A., additional, Shin, Maria, additional, Schroeder, Aaron, additional, Belousov, Anton, additional, Li, Haocheng, additional, Knapp, Andrea, additional, Wei, Michael C., additional, Purev, Enkhtsetseg, additional, and Bottos, Alessia, additional

Published
2022
Full Text
View/download PDF

42. Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Author

Budde, Elizabeth L., primary, Bartlett, Nancy L., additional, Giri, Pratyush, additional, Schuster, Stephen J., additional, Assouline, Sarit, additional, Yoon, Sung-Soo, additional, Fay, Keith, additional, Matasar, Matthew J., additional, Gutierrez, Norma C., additional, Marlton, Paula, additional, Dreyling, Martin, additional, Yoon, Dok Hyun, additional, Hess, Georg, additional, Radford, John, additional, Wiebking, Volker, additional, Yin, Shen, additional, Cybulski, Eva, additional, Turner, David C., additional, Huang, Huang, additional, Zhou, Mingzhu, additional, Penuel, Elicia, additional, Wei, Michael C., additional, and Sehn, Laurie H., additional

Published
2022
Full Text
View/download PDF

43. Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Author

Bartlett, Nancy L., primary, Sehn, Laurie H., additional, Matasar, Matthew J., additional, Schuster, Stephen J., additional, Assouline, Sarit, additional, Giri, Pratyush, additional, Kuruvilla, John, additional, Canales, Miguel, additional, Dietrich, Sascha, additional, Fay, Keith, additional, Ku, Matthew, additional, Nastoupil, Loretta J., additional, Wei, Michael C., additional, Yin, Shen, additional, To, Iris, additional, Huang, Huang, additional, Min, Juliana, additional, Penuel, Elicia, additional, and Budde, L. Elizabeth, additional

Published
2022
Full Text
View/download PDF

44. Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Author

Olszewski, Adam J., primary, Budde, L. Elizabeth, additional, Chavez, Julio, additional, Ghosh, Nilanjan, additional, Kamdar, Manali, additional, Lossos, Izidore S., additional, Diefenbach, Catherine, additional, Sabry, Waleed, additional, Dorritie, Kathleen, additional, Huw, Ling-Yuh, additional, Pham, Song, additional, Jia, Ting, additional, Wu, Hao, additional, To, Iris, additional, Wei, Michael C., additional, and Assouline, Sarit, additional

Published
2022
Full Text
View/download PDF

46. Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

Author

Budde, Elizabeth L, primary, Sehn, Laurie H, additional, Matasar, Matthew, additional, Schuster, Stephen J, additional, Assouline, Sarit, additional, Giri, Pratyush, additional, Kuruvilla, John, additional, Canales, Miguel, additional, Dietrich, Sascha, additional, Fay, Keith, additional, Ku, Matthew, additional, Nastoupil, Loretta, additional, Wei, Michael C, additional, Yin, Shen, additional, Doral, Michelle Y, additional, Li, Chi-Chung, additional, Huang, Huang, additional, Negricea, Raluca, additional, Penuel, Elicia, additional, O'Hear, Carol, additional, and Bartlett, Nancy L, additional

Published
2022
Full Text
View/download PDF

48. IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study

Author

Schuster, Stephen J., Sehn, Laurie H., Bartlett, Nancy L., Matasar, Matthew, Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Shadman, Mazyar, Cheah, Chan Y., Dietrich, Sascha, Fay, Keith, Nastoupil, Loretta, Wei, Michael C., Yin, Shen, To, Iris, Huang, Jiangeng, Kwan, Antonia, Penuel, Elicia, and Budde, L. Elizabeth

Published
2024
Full Text
View/download PDF

49. ABCL-185 Mosunetuzumab with Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

Author

Assouline, Sarit, Elizabeth Budde, Lihua, Chavez, Julio C., Diefenbach, Catherine S., Anne Dorritie, Kathleen, Ghosh, Nilanjan, Olszewski, Adam J., Lossos, Izidore S., Mehta, Amitkumar, Modi, Dipenkumar, Naik, Seema, Douglas Smith, Stephen, Makadia, Sneha, Pham, Song, Wu, Hao, Lee Batlevi, Connie, To, Iris, Wei, Michael C., and Kamdar, Manali

Published
2024
Full Text
View/download PDF

50. Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study

Author

Schuster, Stephen J., Sehn, Laurie H., Bartlett, Nancy L., Matasar, Matthew, Assouline, Sarit, Giri, Pratyush, Kuruvilla, John, Shadman, Mazyar, Cheah, Chan Y., Dietrich, Sascha, Fay, Keith, Ku, Matthew, Nastoupil, Loretta, Wei, Michael C., Yin, Shen, To, Iris, Huang, Jiangeng, Kwan, Antonia, Penuel, Elicia, and Elizabeth Budde, L.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results